PTC/SB/08a(04-07)
Approved for use through 7/31/2006 OA/B 0651-0031
US Paser & Tradema Office, U.S. DEPARTMENT OF COACGRCE
of information unless it organizes a visited GMB control number.

Gabatita	le for form 1449A					
INFO	RMATION	DISCLOSU	RE		Complete if Known	
STATEMENT BY APPLICANT				Application Number	10/522,207	
				Filing Date	October 27, 2005	
				First Named Inventor	Mezher Ali et al.	
				Art Unit	1625	
				Examiner Name	Celia C. Chang	
í	Use as many she	ets as necessary)				
·				Attorney Docket No: AC-22-US		

US PATENT DOCUMENTS						
Examiner initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T²	

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		SILVA, et al., Advances in Prodrug Design, Mini-Reviews in Medicinal Chemistry, 2005, Vol. 5, pp. 893-914.	
		WU, W. et al., Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug, J. Med. Chem., 2007, Vol. 50(15); pp. 3743-3746.	
_		YILDIZ, Y. et al., Mutation of β-glucosidase 2 causes glycolipid storage disease and impaired male fertility, The Journal of Clinical Investigation, 2006, Vol. 116, No. 11, pp. 2985-2994.	